News Scribe Therapeutics joins the IPO queue Scribe Therapeutics has become the latest biotech to announce plans to list on the Nasdaq as it advances its spin on CRISPR-based therapeutics.
News Intellia shares fall after hospitalised CRISPR patient dies Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its clinical trials died.
News CRISPR biotech Intellia plummets as trial paused for safety Intellia lost 45% of its value today as phase 3 trials of one of its priority drug programmes were halted due to a patient being hospitalised.
R&D How a century-old technology could revolutionise LNP charact... The utility of AUC in LNP characterisation is growing, thanks to ongoing efforts to improve the technology.
R&D On incentivisation and investment in rare disease R&D To mark Rare Disease Day, pharmaphorum spoke with Paola Pozzi, partner of telethon strategy at Sofinnova Partners, about the outlook for investment in this field of research.
News CRISPR biotech Intellia cuts staff as it eyes 2027 launch Eyeing a first commercial launch in 2027, Intellia is re-prioritising by cutting 27% of its workforce and shelving a lung disease candidate.
News Scribe Therapeutics joins the IPO queue Scribe Therapeutics has become the latest biotech to announce plans to list on the Nasdaq as it advances its spin on CRISPR-based therapeutics.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
